NCT00595101View on ClinicalTrials.gov

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

PF-03187207

DRUG

Latanoprost 0.005%

DRUG

PF-03187207 Vehicle

One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.

DRUG

Latanoprost Vehicle

Trial Locations (13)

Unknown

Pfizer Investigational Site, Narashino

Pfizer Investigational Site, Shimachi

Pfizer Investigational Site, Kawasaki

Pfizer Investigational Site, Kasukabe

Pfizer Investigational Site, Fuji

Pfizer Investigational Site, Mishima

Pfizer Investigational Site, Susono

Pfizer Investigational Site, Hachiōji

Pfizer Investigational Site, Hamura

Pfizer Investigational Site, Minato

Pfizer Investigational Site, Musashino

Pfizer Investigational Site, Setagaya City

Pfizer Investigational Site, Shizuoka

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00595101 - A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. | Biotech Hunter | Biotech Hunter